Who is moving to which position
Resolved 6 May 2026Incoming appointee
1 itemThe Company will stabilize its management foundation by introducing a two-person representative executive structure comprising the Representative Executive Officer and President and the Representative Executive Officer and Executive Vice President. By granting representative authority to Matsui Ryosuke (松井亮介), who has broadly overseen the practical aspects of the Group's financial strategy and operations, the Company will distribute management responsibilities and strengthen its executive structure.
| Item | Details |
|---|---|
| Resolution date | 6 May 2026 |
| Scheduled Appointment Date | Effective 6 May 2026 (change in the Company's officers). The change in the subsidiary's officers is effective 4 May 2026. |
| Name of appointee | Matsui Ryosuke (松井亮介) |
| Appointee's new position | Director, Representative Executive Vice President, COO and CFO; Director of ZOO LABO Co., Ltd.; Board of Managers of Berkeley Advanced Biomaterials LLC; Board of Managers of Berkeley Biologics LLC |
| Appointee's previous position | Director, Executive Vice President, COO and CFO; Director of ZOO LABO Co., Ltd.; Board of Managers of Berkeley Advanced Biomaterials LLC; Board of Managers of Berkeley Biologics LLC |
| Appointee's date of birth | 23 April 1979 |
| Number of shares held by the appointee | 79,800 shares (as of 31 December 2025) |
| Reason for change | The Company will stabilize its management foundation by introducing a two-person representative executive structure comprising the Representative Executive Officer and President and the Representative Executive Officer and Executive Vice President. By granting representative authority to Matsui Ryosuke (松井亮介), who has broadly overseen the practical aspects of the Group's financial strategy and operations, the Company will distribute management responsibilities and strengthen its executive structure. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate new drug development by integrating the technology and development functions of Gyre and Cullgen, and to distribute management responsibilities and strengthen the executive structure, facilitate prompt decision-making and stabilize the management foundation by granting representative authority to Matsui Ryosuke (松井亮介). In addition, the waiver of accrued unpaid interest on Cullgen's preferred shares will result in the recognition of a gain on debt forgiveness, and annual interest expense equivalent to approximately ¥1.5 billion is expected to be eliminated.